353results about How to "Enhance killing activity" patented technology

Frequent application of a virucidal hand lotion containing malic acid, citric acid, and a C1-6 alcohol will prevent the hand-to-hand transmission of rhinoviruses and reduce the incidence of the "common cold" caused by rhinoviruses.

The present invention discloses a novel chimeric antigen receptor and applications thereof, wherein the novel chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a transmembrane domain and an intracellular signal domain, and comprises a 4-1BB signal peptide and/or a 4-1BB molecular transmembrane domain. According to the present invention, a variety of chimeric antigenreceptor nucleic acid sequences are separated and purified, the chimeric antigen receptor specifically for CD19 malignant tumor antigens and the CAR-T cells are provided, and the blood cell line malignant tumor killing test results show that the tumor-cell-targeting ability of immune cells is significantly enhanced, and the tumor cell killing activity is enhanced.

The antimicrobial composition of the present invention comprises a cationic active ingredient, a quaternized sugar-derived surfactant, and an optional foam boosting surfactant. The present antimicrobial compositions are free of the antimicrobial agent triclosan (i.e., 2,4,4′-trichloro-2′hydroxy-diphenylether), have a high cidal activity in a short amount of time, provide stable copious foam and exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method.

The invention discloses a method for amplifying NK cells of human beings under the condition of in vitro culture, which is characterized in that a peripheral blood mononuclear cell (PBMC) is taken asthe original culturing material, and the PBMC is cultured together with an engineering cell which is built by adopting the genetic engineering method and is used for stimulating the growth of the NK cell. The built engineering cell which is used for stimulating the growth of the NK cell expresses several cytokines (IL-2, IL-12, IL-15, IL-18, 4-1BB) which can promote the growth of the NK cell on the surface of the K562 cell; after irradiation and inactivation with gamma-rays, the engineering cell is cultured with the PBMC in vitro, as a result, the amplification effect of the stimulation methodin the invention is hundreds of times stronger than that of the currently universal method in which soluble cytokines are added purely to the culture solution; and after cultured for 3 weeks, the non-NK cells in the PBMC are mainly dead and disappeared, the NK cells are proliferated in great quantity, the purity of the NK cells reaches over 96% and the total number of the NK cells is amplified byover 1500 times.

The invention discloses a method for simultaneous and efficient amplification of CD<3+>CD<56+>CIK cells and CD<3->CD<56+>NK cells. The method comprises the steps as follows: the concentration of separated PBMC (peripheral blood mononuclear cells) is adjusted by a serum-free medium containing autologous plasma, an Anti-CD16 antibody, IL-2 and IL-15 are added, and then the mixture is transferred into a T175 culture flask for culture; an Anti-CD3 antibody and an Anti-CD137 antibody are added; a serum-free medium containing the autologous plasma, IL-2 and IL-15 is supplemented every two days according to the cell growth condition; the cell concentration is controlled to be about 1.5*10<6>/ml; and after culture is performed for 14-21 days, large quantities of high-purity CD<3+>CD<56+>CIK cells and CD<3->CD<56+>NK cells can be obtained simultaneously, and the total cell quantity can reach an effective value of the cell quantity required for adoptive cellular immunotherapy clinically for tumor. The method for simultaneous and efficient amplification of the CD<3+>CD<56+>CIK cells and the CD<3->CD<56+>NK cells is simple, convenient, effective and high in cell killing activity.

The invention relates to an antibody having at least two specificities to bind a glycoepitope and a receptor of the erbB class on the surface of a tumor cell, thereby crosslinking the glycoepitope and the receptor, which antibody has apoptotic activity effecting cytolysis independent of NK cells, a method of producing such antibody and its use as a therapeutic.

The invention relates to a culture method of autologous peripheral blood lymphocyte DC-CIK. The culture method comprises the following steps: (1) separating mononuclear cells of peripheral blood; (2) conducting isolated culture of DC cells; (3) conducting induced culture of CIK cells; (4) co-culture the DC and CIK cells to prepare DC-CIK cells, and adding 100 ng/mL of CTLA-4 (Cytotoxic Lymphocyte Antigen) mAb and 100 ng/mL of PD-1 (Programmed Cell Death-1) mAb; (5) centrifuging and collecting the cultured DC-CIK cells. The culture method disclosed by the invention is to add a plurality of monoclonal antibodies and cell factors in a blood serum medium to increase the activation efficiency and the amplification efficiency of the effector cell colony, in particular load the CTLA4 antibodies and the PD-1 antibodies in vitro to cover the CTLA4 and PD-1 molecules on the surface of all the CIK cells, and enable the molecules not to be bound with corresponding receptors on the DC, so as to effectively reduce the content of T regulatory cells, and further improve the lethal effect of the CIK cells on tumors.

The invention discloses a novel CAR (Chimeric Antigen Receptor) and application of novel CAR modified T cells for treating cancer. The novel CAR is formed by an extracellular signal peptide, an antigen binding structural domain, an intracellular first conduction structural domain and an intracellular second conduction structural domain, and contains an intracellular first conduction structural domain NKp44 or an intracellular first conduction structural domain TREM1. According to the novel CAR disclosed by the invention, multiple CAR nucleotide sequences are separated and purified, and the CARand CAR-T cells which specifically aims at CD19 malignant hematologic tumor and mesothelin malignant solid tumor antigens. In a hematologic tumor and solid tumor killing test, the killing capacity ofthe CAR-T cells to tumor cells is obviously enhanced, and good safety and good anti-tumor activity in clinic application are expressed.

The invention discloses a chimeric antigen receptor, a coding gene, an expression vector and application thereof. The chimeric antigen receptor comprises a single chain variable fragment, a CD8 alpha transmembrane domain, a CD3 zeta intracellular signal domain, a first co-stimulator ligand and a second co-stimulator ligand which are in successive tandem connection, wherein the CD8 alpha transmembrane domain is used for connecting the single chain variable fragment to a cell membrane, 2A short peptide is arranged between and in tandem connection with the CD3 zeta intracellular signal domain and the first co-stimulator ligand, and another 2A short peptide is arranged between and in tandem connection with the first co-stimulator ligand and the second co-stimulator ligand. According to the chimeric antigen receptor provided by the invention, the 2A short peptide is used to connect the chimeric antigen receptor with the two co-stimulator ligands, so the two co-stimulator ligands are expressed on the surface of an immune cell at the same time; once the chimeric antigen receptor specifically binds with antigen, the two co-stimulator ligands rapidly migrate to synapses formed by the combination of cells, so activity of immune cells is effectively enhanced.

The invention provides novel synthesis antibacterial peptides and application thereof. The novel synthesis antibacterial peptides are designed and synthesized on the basis of analyzing sequences and structures of natural antibacterial peptides, and the sequences of the novel synthesis antibacterial peptides comprise WYQ-a: ArgArgTrpTrpArg and WYQ-b: PheArgTrpTrpArg. The synthesis antibacterial peptides have the broad spectrum killing activity on gram-positive bacteria and gram-negative bacteria, have higher bactericidal activity than that of the natural antibacterial peptides, and do not have a toxic effect on animal and plant cells. The synthesis antibacterial peptides have broad antibacterial spectra and simple structures, are not needed to be modified and connected and are convenient to synthesize artificially. Experiments prove that: for G+bacteria (the gram-positive bacteria) and G-bacteria (the gram-negative bacteria), the novel synthesis antibacterial peptides have the obvious bacteriostatic and bactericidal activity and do not have hemolysis activity, so the synthesis antibacterial peptides have significant value in the development and application of antibacterial medicines.

The invention relates to a separation and efficient amplification culture method for an antigen specific T lymphocyte. By means of the immunomagnetic bead technology and the character of an active T cell expression CD137, the antigen specific T lymphocyte is separated from a complex cell mass; then an antigen specific T lymphocyte with high tumor killing activity is obtained through in-vitro efficient amplification culture. CD137L (CD137-ligand), IL-7, IL-15 and IL-2 are added in the culturing process, so that the phenomenon that activated and induced cells are liable to apoptosis in the culturing process is avoided, the amplification time is increased, and the killing activity of the antigen specific T lymphocyte is improved.

The invention provides a type of fused heterocycle compounds containing pyrazolone rings, optical isomers, cis-trans-isomers or pharmaceutically acceptable salts of fused heterocycle compounds and applications of the fused heterocycle compounds, and the optical isomers, cis-trans-isomers or pharmaceutically acceptable salts of the fused heterocycle compounds. The fused heterocycle compounds have astructure represented by a formula (I) (shown in the description). The fused heterocycle compounds containing the pyrazolone rings, and the optical isomers, the cis-trans-isomers or the pharmaceutically acceptable salts of the fused heterocycle compounds have high killing activity to agriculture and forestry pests, health pests and the like, furthermore, and the compounds have a delayed action effect to pests such as red imported fire ants, so the pests can carry the drug to a nest, and the whole nest and an queen ant can be well killed; and the compounds have very good application prospects.

The invention relates to a tumor tissue tumor infiltrating lymphocyte (TIL) cell preparation method and a dedicated culture medium. The method comprises the following steps of tumor surrounding tissue obtaining, cell digestion, cell primary culture, cell subculture and cell collection, wherein a primary culture medium is based on a RPMI 1640 culture medium and prepared from the following concentration ingredients of 10% volume of human-derived serum, 20 to 45ng/ml of basic fibroblast growth factor (bFGF), 1 to 5mg/ml of riboflavin, 70 to 90ng/ml of cortisol, 10 to 25mg/ml of sodium dihydrogen phosphate monohydrate, 47 to 62ng/ml of recombinant human leukaemia inhibitory factor (LIF) and 500 to 800U/ml of IL-2; a subculture medium is based on the RPMI 1640 culture medium and prepared from the following concentration ingredients of 10% volume of the human-derived serum, 20 to 40mmol/L of HEPES, 1000 to 2000U/ml of the IL-2, 0.03 to 0.07mmol/L of beta-mercaptoethanol and 5 to 15ng/ml of sodium phosphate. According to the preparation method, an existing culture medium is improved, different culture mediums are utilized to culture the TIL cells in pertinence, TIL cell expansion capacity is improved, meanwhile a culture period is reduced, a culture complexity degree is reduced, a use amount of the IL-2 is reduced, and toxic reaction is reduced.

The invention discloses an environmentally-friendly pesticide synthesized by utilizing oleander extract. The environmentally-friendly pesticide comprises an oleander active ingredient which is oily extract obtained by soaking and extracting oleander broken leaves. The solvent of the pesticide is water or an ethyl alcohol solution; the concentration of the oleander active ingredient is 100mg/L to 600mg/L; ciprofloxacin for corrosion prevention is added in the pesticide. The data analysis indicates that the higher the concentration of the extract liquid of the oleander leaves, the stronger the toxicity. The insecticidal action of the oleander extract liquid is needed to be completed with a certain time, and therefore, the pesticide is a non-quick-acting pesticide, and can be developed and utilized as a slow-release plant source pesticide. The pesticide prepared by the oleander extract disclosed by the invention provides a more effective means for the biological pesticide for comprehensive treatment for the pest and disease damage; the oleander has high killing activity for ampullaria gigas, porthesia similis and diplopod, has simply and easily available materials, and is a very excellent environmentally-friendly pesticide.

The invention discloses a method for preparing cytokine-induced killer (CIK) cells. The method comprises the following steps: 1) collecting and separating individual karyocytes from peripheral blood; 2) placing the individual karyocytes obtained in the step 1) in a culture medium suitable for lymphocytes, removing monocytes by the adherence characteristic of the monocytes, and adding CD3 monoclonal antibodies, interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) in the rest to culture the lymphocytes to CIK cells; and 3) culturing the culture solution obtained in the step 2) for 8-15 days, and then adding interferon-alpha (IFN-alpha) and IL-2 to culture continuously. Compared with the cells which are cultured without adding IFN-alpha, the cells cultured by the method have higher killing property to tumor cells which is increased by 50%-200%. Through the clinical treatments of more than 100 malignant tumor patients, the response rate which is related to the progressive disease (PR), the complete response (CR), the magnetic resonance imaging (MR) and the stable disease (SD) can reach 75%, wherein the response rate (PR+CR+MR) can reach 50%. By adopting the method for preparing CIK cells, the life cycle of advanced tumor patients can be prolonged and the life quality of the patients can be increased.

The invention relates to the novel usage of an antimalarial medicine, in particular to the novel usage of hydroxychloroquine having sensitivity enhancing effect on various chemical anti-multiple myeloma medicaments. The novel usage is characterized in the application of hydroxychloroquine in treatment of multiple myeloma through chemotherapeutic medicaments. The hydroxychloroquine can obviously enhance the killing activity of chemotherapeutic medicines such as doxorubicine, epidoxorubicin, cis-platinum and mitoxantrone to multiple myeloma cells, and the killing activity thereof is realized by inhibiting the myeloma cell autophagy signals by hydroxychloroquine. Hydroxychloroquine can induce the quantity of the autophagy lysosomes of the multiple myeloma cells to be increased and the expression of the autophagy-associated albumen LC3-II to be increased.

The invention discloses application of an engineered T cell with an immune receptor for treatment of cancer. A chimeric antigen receptor consists of an extracellular signal peptide, an antigen bindingstructural domain, a first intracellular conduction structural domain and a second intracellular conduction structural domain and comprises the first intracellular conduction structural domain in theform of the immune receptor. The invention provides a plurality of amino acid sequences of the chimeric antigen receptor and provides the chimeric antigen receptor specific for CD19 malignant hematological tumors and CAR-T cells. In a blood tumor killing test, the ability of the CAR-T cells to kill tumor cells is significantly improved, and high safety and high antitumor activity are shown in clinical application.

The invention provides a production process of an environment-friendly air filtration non-woven fabric, and belongs to the technical field of air filtration. Polypropylene, electret master batch and high-molecular electret are uniformly mixed, the prepared mixture is fed into a screw extruder, melt extrusion is performed through the screw extruder to form a melt, the melt is sprayed out through a spinneret plate to form fibers, the fibers are subjected to constant-temperature and constant-pressure hot air drafting, melt-blown cloth is formed on a web curtain, then infrared radiation heat treatment, high-pressure electret treatment and cooling treatment are sequentially conducted, then rolling is conducted, and the air filtration non-woven fabric is obtained, wherein electret master batches are composed of polypropylene, few-layer graphene nanosheets, an antioxidant, a compatilizer and a nucleating agent; the few-layer graphene nanosheet is prepared by taking magnesium oxide microcrystals with a face-centered cubic structure as a substrate and a template through a chemical vapor deposition method; and the electret master batch improves the electret degree of fibers, improves the storage stability of charges and further improves the filtering performance.

The invention discloses an in-vitro amplification method of natural killer cells (NK). The in-vitro amplification includes the steps of S1, culturing mononuclear cells separated from peripheral blood with a serum-free medium while adding in IFN-gamma to stimulate for a first preset time; S2, adding class-I cell factors in the serum-free medium for stimulation induction after the first preset time; S3, adding in class-II cell factors in the serum-free medium for induced amplification after culturing for a second preset time, and then performing cell fluid replacement and culturing for a third preset time; and S4, collecting the cells. According to embodiments of the invention, the natural killer cells cultured by the in-vitro amplification method have high killing action and high significant effect to target cells.